Interferon for hepatocellular carcinoma

The objectives of this systematic Review are to try to answer the following questions based on the results of randomised clinical trials (RCTs) comparing IFN versus no intervention, placebo, or other interventions irrespective of blinding, publication status, or language:
1) Does IFN reduce mortality and tumour recurrences in patients with HCC when used as primary treatment?
2) Does IFN reduce mortality and tumour recurrences when used as adjuvant or neoadjuvant therapy in patients treated by surgical or other ablative procedures?
3) Does IFN cause adverse events?
4) Does IFN affect quality of life and health economics?

This is a protocol.

Share/Save